Epidemiological studies have shown that increased levels of circulating IGF-I or increased IGF-I relative to IGFBP-3 are associated with a higher risk of developing several forms of cancer, including prostate and breast cancers [7–12]. This evidence concerns the gene IGF1 and breast carcinoma.